


# Panel Discussion and Audience Q&A

**Kathleen Moore, MD**



# Discussion

1. What are some potential ADC combinations that may lead to increased clinical benefit of ADCs, especially in PROC?
2. How might ADCs like mirvetuximab soravtansine change the landscape of treatment options for individuals with platinum-resistant tumors, offering a more favorable risk-benefit profile?
3. What are the roles of a multidisciplinary team in the management and monitoring of ADC adverse events?